Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy
Authors:
Open Access
- 31 January 2023
- journal article
- editorial
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (6)
Abstract
No abstract availableFunding Information
- IZKF Muenster (SEED/016/21)
- Deutsche Forschungsgemeinschaft (CRCTR128 Z02)
This publication has 23 references indexed in Scilit:
- Immune reconstitution therapies: concepts for durable remission in multiple sclerosisNature Reviews Neurology, 2019
- Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosisBrain, 2018
- Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple SclerosisCell, 2018
- Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of AlemtuzumabJAMA Neurology, 2017
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple SclerosisNew England Journal of Medicine, 2017
- VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cellsJournal of Experimental Medicine, 2014
- Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis PatientsThe Journal of Immunology, 2014
- Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trialThe Lancet, 2011
- IMMUNOLOGY OF MULTIPLE SCLEROSISAnnual Review of Immunology, 2005
- Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrinNature, 1992